Sokolakis I, Pyrgidis N, Koneval L, et al. - In this study, the usability and diagnostic accuracy for prostate cancer of three multiparametric magnetic resonance imaging (mpMRI)/transrectal ultrasound (TRUS)-guided fusion biopsy systems operated by the same urologists were investigated. Researchers carried out a prospective, observational study including patients that had undergone prostate biopsy due to a visible lesion in mpMRI (PI-RADS ≥ 3). They consecutively evaluated two platforms with a rigid image registration (BioJet, D&K Technologies and UroNav, Invivo Corporation) and one with an elastic registration (Trinity, KOELIS). The study included 60 consecutive patients that received mpMRI/TRUS-guided prostate biopsy with the BioJet (n = 20), UroNav (n = 20) or Trinity (n = 20) fusion system. In comparison with elastic systems, rigid fusion biopsy systems are easier to use and provide shorter operative time, while both types of platforms display similar detection rates for prostate cancer. Still, future high-quality, long-term outcomes are mandatory.